Heat Biologics Announces Formation of Biothreat Advisory Board
18 Août 2021 - 2:00PM
Heat Biologics, Inc. (“Heat”)
(NASDAQ: HTBX), a clinical-stage
biopharmaceutical company focused on developing first-in-class
therapies to modulate the immune system, announces it has commenced
development of a new biosecurity/biodefense initiative. The Company
also announces it has formed an advisory board to support this
initiative. Joining the new advisory board are David Lasseter,
Former Deputy Assistant Secretary of Defense for Countering Weapons
of Mass Destruction, and Former US Representative Jack Kingston.
Jeff Wolf, Chief Executive Officer of Heat,
commented, “This biosecurity/biodefense initiative was initially
conceived as a result of our research following the COVID-19
pandemic. We recognized the need for versatile and timely response
solutions to protect the U.S. against known or unknown future
biological threats and embarked on the development of a platform to
address this issue. I am pleased to welcome both David Lasseter and
Representative Jack Kingston to our newly formed board of advisors.
As Former Deputy Assistant Secretary of Defense for Countering
Weapons of Mass Destruction (WMD), Mr. Lasseter had direct
oversight over the country’s biological defense programs. During
his tenure in Congress, Rep. Kingston was a leading member of the
House Appropriations Committee and the Defense Appropriations
Subcommittee, and is currently Secretariat of The Alliance for
Biosecurity. I believe their expertise will be invaluable to our
initiative and I look forward to providing further details as we
roll out this highly differentiated approach.”
David F. Lasseter was the Deputy Assistant
Secretary of Defense for Countering Weapons of Mass Destruction
where he was responsible for, among other issues, all strategies
and policies concerning preventing the proliferation of WMD and
WMD-related materials; the United States Department of Defense
(DoD) Cooperative Threat Reduction Program; and Chemical,
Biological, Radiological and Nuclear (CBRN) defense. Prior to this,
Mr. Lasseter worked for United Technologies Corporation as the lead
defense government relations professional. He has served as a
Congressional chief of staff, military legislative assistant, and
counsel. He is also a Marine Corps intelligence officer in the
reserve component. Mr. Lasseter received his undergraduate degree
from the University of Georgia and a juris doctor from the
University of Alabama.
Former US Representative Jack Kingston is a
Principal at Squire Patton Boggs, a premier, full-service global
law firm that helps clients address public policy challenges in
legislatures and regulatory agencies around the world. He also
serves as Secretariat for The Alliance for Biosecurity, which
promotes a stronger, more effective partnership between government,
the biopharmaceutical industry, and other stakeholders in seeks to
advance their shared goal of developing critically needed medical
countermeasures. The Alliance also seeks to develop sound public
policy proposals that could bolster national efforts to rapidly
develop, produce, stockpile, and distribute medical
countermeasures. In Congress, Rep. Kingston earned a reputation as
an effective legislator with a keen ability to resolve complex
matters by reaching across the aisle. Rep. Kingston’s leadership of
the largest domestic appropriations subcommittee and his senior
position on the defense appropriations subcommittee give him a deep
understanding of the policy and financial challenges global clients
face. In addition, Rep. Kingston assists with strategic counseling
for the firm’s leadership in defense related issues and other
specialty areas. Rep. Kingston served Georgia's 1st Congressional
District in Southeast Georgia from 1993 to 2015. He also served as
vice-chairman of the House Republican Conference, the sixth-ranking
post among House Republicans, from 2002 to 2006.
David Lasseter further noted, “Time is of the
essence when responding to a pandemic or biological threat. I look
forward to working closely with Heat to advance their unique and
proprietary biodefense initiative to rapidly address urgent
national security needs.”
About Heat Biologics, Inc.Heat
Biologics is a biopharmaceutical company focused on developing
first-in-class therapies to modulate the immune system. Heat’s gp96
platform is designed to activate immune responses against cancer or
infectious diseases. The Company has multiple product candidates in
development leveraging the gp96 platform, including HS-110, which
has completed enrollment in its Phase 2 trial, various infectious
disease/biological threat programs in preclinical development and a
pipeline of proprietary immunomodulatory antibodies and cell-based
therapies, including PTX-35 and HS-130 in Phase 1 clinical
trials.
For more information, please
visit: www.heatbio.com, and also follow us
on Twitter.
Forward Looking StatementThis
press release includes forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 on
our current expectations and projections about future events. In
some cases, forward-looking statements can be identified by
terminology such as "may," "should," "potential," "continue,"
"expects," "anticipates," "intends," "plans," "believes,"
"estimates," and similar expressions. These statements are based
upon current beliefs, expectation, and assumptions and include
statements regarding the contributions to be made by the advisory
board, the expertise of David Lasseter and Jack Kingston being
invaluable to Heat’s biosecurity/biodefense initiative and
providing further details as we roll out our new
biosecurity/biodefense initiative. These statements are subject to
a number of risks and uncertainties, many of which are difficult to
predict, including the ability of Heat to successfully develop a
new biosecurity/biodefense initiative and benefit from the
contributions of the advisory board, the ability of Heat's
therapies to perform as designed, to demonstrate safety and
efficacy, as well as results that are consistent with prior
results, the ability to enroll patients and complete the clinical
trials on time and achieve desired results and benefits, especially
in light of COVID-19, Heat's ability to obtain regulatory approvals
for commercialization of product candidates or to comply with
ongoing regulatory requirements, regulatory limitations relating to
Heat's ability to promote or commercialize its product candidates
for specific indications, acceptance of its product candidates in
the marketplace and the successful development, marketing or sale
of products, Heat's ability to maintain its license agreements, the
continued maintenance and growth of its patent estate, its ability
to establish and maintain collaborations, its ability to obtain or
maintain the capital or grants necessary to fund its research and
development activities and its cash and short-term investments
providing significant runway to fund Heat’s current clinical
programs and further expand Heat’s therapeutic portfolio , its
ability to continue to maintain its listing on the Nasdaq Capital
Market and its ability to retain its key scientists or management
personnel, and the other factors described in Heat's annual report
on Form 10-K for the year ended December 31, 2020 filed with the
SEC, and other subsequent filings with the SEC. The information in
this release is provided only as of the date of this release, and
Heat undertakes no obligation to update any forward-looking
statements contained in this release based on new information,
future events, or otherwise, except as required by law.
Media and Investor Relations ContactDavid
Waldman+1 919 289 4017investorrelations@heatbio.com
Heat Biologics (NASDAQ:HTBX)
Graphique Historique de l'Action
De Août 2024 à Sept 2024
Heat Biologics (NASDAQ:HTBX)
Graphique Historique de l'Action
De Sept 2023 à Sept 2024